Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20...

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Epidermal growth factor receptor (EGFR) Exon20 insertion mutations are a significant challenge in non-small cell lung cancer treatment.
• Existing therapies often lack efficacy or exhibit poor selectivity against these specific mutations.
• Developing targeted inhibitors with improved pharmacokinetic properties, including blood-brain barrier penetration, is crucial.

Purpose of the Study:

• To optimize novel epidermal growth factor receptor (EGFR) Exon20 insertion (Ex20Ins) inhibitors through structure-based drug design (SBDD).
• To identify a potent, wild-type selective inhibitor with favorable properties for central nervous system delivery.
• To advance preclinical efficacy in relevant cancer models.

Main Methods:

• Structure-based drug design (SBDD) was employed to iteratively modify lead compounds.
• Novel bicyclic cores were designed to enhance blood-brain barrier penetration.
• Optimization focused on linker replacement and c-helix interacting ring diversification for improved stability.
• Molecular properties such as molecular weight, H-bonding, and polarity were refined for optimal brain exposure.

Main Results:

• Compound 28 was identified as a potent and wild-type selective EGFR Exon20 insertion inhibitor.
• Compound 28 demonstrated significant efficacy in multiple EGFR Ex20Ins xenograft models.
• Preclinical studies confirmed blood-brain barrier penetration of compound 28.
• Optimization led to improvements in photolytic and metabolic stability.

Conclusions:

• Compound 28 represents a promising therapeutic candidate for EGFR Exon20 insertion-mutated cancers.
• The developed molecule exhibits favorable properties for brain penetration, addressing a key challenge in CNS oncology.
• Structure-based drug design effectively guided the discovery of a potent and selective inhibitor with enhanced stability and brain exposure.